Sana Biotechnology (SANA) vs Solid Biosciences (SLDB)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Solid Biosciences (SLDB) has outperformed Sana Biotechnology (SANA) over the past year, gaining 8.1% versus a loss of 38.4%. Over five years, SLDB leads with a -79.8% price change compared with -86.6% for SANA. Sana Biotechnology is the larger company by market cap ($835.2 million vs $736.6 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | SANA | SLDB |
|---|---|---|
| Share price | $2.79 | $6.87 |
| Market cap | $835.22M | $736.64M |
| 1-day change | 0.00% | +0.73% |
| YTD return | -31.45% | +20.92% |
| 1-year return | -38.41% | +8.08% |
| 5-year return | -86.58% | -79.79% |
| EPS (TTM) | $-0.76 | $-1.89 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $6.55 | $11.45 |
| 52-week low | $2.61 | $3.79 |
| Distance from 52-week high | -57.40% | -40.00% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +202.15% | +171.03% |
| Average volume | 3.13M | 1.10M |
| Shares outstanding | 299.36M | 107.23M |
| Employees | 142 | 121 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- SLDB has outperformed SANA by 46.5 percentage points over the past year.
About Sana Biotechnology
SANA stock →Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines in the United States. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including type 1 diabetes, B cell mediated autoimmune diseases, and oncology.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 142 employees
About Solid Biosciences
SLDB stock →Solid Biosciences Inc. develops therapies for neuromuscular and cardiac diseases in the United States.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 121 employees
SANA vs SLDB FAQ
Which is bigger, Sana Biotechnology or Solid Biosciences?
Sana Biotechnology (SANA) is larger, with a market capitalization of $835.22M compared with $736.64M for Solid Biosciences (SLDB).
Which stock has performed better over the past year, SANA or SLDB?
SLDB returned +8.08% over the past 12 months, compared with -38.41% for SANA (price return, excluding dividends). Past performance does not predict future results.
Are Sana Biotechnology and Solid Biosciences in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.